Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer
NCT ID: NCT00081315
Last Updated: 2007-08-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
130 participants
INTERVENTIONAL
2003-11-30
2006-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amifostine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have never had prior chemotherapy with Paclitaxel or Carboplatin
* Have never had prior thoracic radiation therapy (XRT)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MedImmune LLC
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luz Hammershaimb, M.D.
Role: PRINCIPAL_INVESTIGATOR
MedImmune LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cedars Sanai
Los Angeles, California, United States
Radiation Oncology Center
Sacramento, California, United States
The Center for Cancer Care
Torrington, Connecticut, United States
Florida Wellcare Alliance
Inverness, Florida, United States
Florida Community Cancer Center
New Port Richey, Florida, United States
Ormand Memorial Cancer Center
Ormand Beach, Florida, United States
Sarasota Memorial Hospital
Sarasota, Florida, United States
University Community Hospital-Center for Cancer Care
Tampa, Florida, United States
University of Kentucky
Lexington, Kentucky, United States
St. Agnes Health Care
Baltimore, Maryland, United States
Center for Cancer & Blood Disorders
Bethesda, Maryland, United States
Chesapeake Oncology-Hematology Associates
Glen Burnie, Maryland, United States
St. John's Medical Research
Springfield, Missouri, United States
Cooper University Hospital
Camden, New Jersey, United States
Long Island Jewish Medical Center
New Hyde Park, New York, United States
Beth Israel Hospital
New York, New York, United States
Upstate NY Cancer R&E Foundation
Rochester, New York, United States
New Hanover Radiation
Wilmington, North Carolina, United States
Cancer Center of Upper Delaware Valley
Milford, Pennsylvania, United States
Montgomery Cancer Center
Norristown, Pennsylvania, United States
Charleston Cancer Center
Charleston, South Carolina, United States
The Center for Radiation Oncology
Danville, Virginia, United States
Providence Everett Medical Center
Everett, Washington, United States
Valley Medical Center
Renton, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MI-CP079
Identifier Type: -
Identifier Source: org_study_id